Otezla for Plaque Psoriasis | Otezla® (apremilast) Professional Site

^*Otezla significantly increased ACR20 response at week 16 vs placebo (38% vs 19%: n = 168 for both; P = 0.0001)^1-3

Resource Center

Download a Letter of Medical Necessity, patient support tools, and more

Explore resources

Proven Efficacy^1-3

Results from clinical trials evaluating the clinical efficacy of Otezla^® (apremilast)

Learn more

Safety

Learn more about the safety results reported in Otezla clinical trials

Learn more

Dosing

Otezla is an oral, non‑biologic therapy^1,2

Learn more

Co-pay^†

Otezla is available to most commercially insured patients for $0

Learn more

Download the Start Form

Otezla significantly increased PASI-75 response (n = 562) at week 16 (primary endpoint) vs placebo (n = 282) (33% vs 5%; P < 0.0001).^1,3

†

Certain restrictions apply; eligibility not based on income, must be 18 years or older. This offer is not valid for persons eligible for reimbursement of this product, in whole or in part under Medicaid, Medicare, or similar state or federal programs. Offer not valid for cash-paying patients. People who are not eligible can call 1-844-4OTEZLA to discuss other financial assistance opportunities.

References: 1. Otezla [package insert]. Summit, NJ: Celgene Corporation. 2. Data on file, Celgene Corporation. 3. Papp K, Reich K, Leonardi CL, et al. J Am Acad Dermatol. 2015;73(1):37-49.